Yamato Kazumi, Tamasawa Naoki, Murakami Hiroshi, Matsui Jun, Tanabe Jutaro, Suda Toshihiro, Yasujima Minoru
Third Department of Internal Medicine, Hirosaki University School of Medicine, Zaifu-5, Hirosaki 036-8562, Japan.
Diabetes Res Clin Pract. 2005 Aug;69(2):124-8. doi: 10.1016/j.diabres.2004.11.008. Epub 2004 Dec 28.
It has been shown that apolipoprotein A-I (ApoA-I) stimulates the secretion of apolipoprotein E (ApoE) from human macrophages. ApoA-I is a major protein constituent of HDL which because of its role in reverse cholesterol transport, has been implicated in the prevention of atherosclerosis. We herein investigated the ability of monocyte-derived macrophages (MDMs) in 42 patients with type 2 diabetes to secrete ApoE; these patients commonly have low plasma HDL and ApoA-I levels. Our data showed that ApoE secretion from these cells was reduced in patients with low plasma HDL and ApoA-I levels; there were positive correlation between ApoE secretion from MDMs and plasma HDL (r2=0.33, p=0.03) and ApoA-I (r2=0.31, p=0.03). Furthermore, we found that ApoE secretion increased concomitantly with an increase in HDL or ApoA-I in treated diabetics (n=24) from 1.99+/-1.86 to 3.40+/-1.77 ng/mg cell protein. These findings suggest another possible link between HDL and ApoA-I metabolism and atherosclerosis in patients with type 2 diabetes.
研究表明,载脂蛋白A-I(ApoA-I)可刺激人巨噬细胞分泌载脂蛋白E(ApoE)。ApoA-I是高密度脂蛋白(HDL)的主要蛋白质成分,因其在逆向胆固醇转运中的作用,被认为与动脉粥样硬化的预防有关。我们在此研究了42例2型糖尿病患者的单核细胞衍生巨噬细胞(MDM)分泌ApoE的能力;这些患者的血浆HDL和ApoA-I水平通常较低。我们的数据显示,血浆HDL和ApoA-I水平低的患者,这些细胞的ApoE分泌减少;MDM分泌的ApoE与血浆HDL(r2 = 0.33,p = 0.03)和ApoA-I(r2 = 0.31,p = 0.03)之间呈正相关。此外,我们发现,在接受治疗的糖尿病患者(n = 24)中,随着HDL或ApoA-I增加,ApoE分泌也随之增加,从1.99±1.86增加到3.40±1.77 ng/mg细胞蛋白。这些发现提示了2型糖尿病患者中HDL和ApoA-I代谢与动脉粥样硬化之间的另一种可能联系。